Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Chief Med and Dev Officer | December 01, 2025 | December 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Crinetics Pharmaceuticals, Inc.
Report date December 01, 2025 · Filed December 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,837 |
Reported balance
After 2025-12-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-01 · Exercise / conversion · Acquired 5,000 · Balance 71,837 F1: Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 66,837 |
Reported balance
After 2025-12-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-12-01 · Sale · Disposed 5,000 · Balance 66,837 F2: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025. F3: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on the transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.89 · Expires 2032-10-10 | Direct | 69,042 |
Reported balance
After 2025-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-01 · Exercise / conversion · Disposed 5,000 · Balance 69,042 F4: The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan.
F2: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
F3: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on the transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F4: The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2024 Filed Mar 6, 2024 20:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004607 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,911 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 14,375 | $0.00 Strike: $16.89 | $0.00 |
DisclosureSEC source: 0001209191-24-000816 · doc4.xml · derivative · entry 3 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,042 Underlying: Common Stock · 14,375 shares Expires 2032-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 14,375 | $35.00 | $503,125.00 |
DisclosureSEC source: 0001209191-24-000816 · doc4.xml · nonDerivative · entry 2 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,911 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.00 per share. The range of sales prices on the transaction date was $34.82 to $35.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 14,375 | $16.89 | $242,793.75 |
DisclosureSEC source: 0001209191-24-000816 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 18:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 9,583 | $0.00 Strike: $16.89 | $0.00 |
DisclosureSEC source: 0001209191-23-059628 · doc4.xml · derivative · entry 3 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,417 Underlying: Common Stock · 9,583 shares Expires 2032-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 18:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 9,583 | $34.57 | $331,284.31 |
DisclosureSEC source: 0001209191-23-059628 · doc4.xml · nonDerivative · entry 2 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,911 F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $34.57 per share. The range of sales prices on the transaction date was $34.50 to $34.67 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 18:45 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 9,583 | $16.89 | $161,856.87 |
DisclosureSEC source: 0001209191-23-059628 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Med and Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,411 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 05, 2023 Filed Apr 5, 2023 19:12 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 8,212 | $16.15 | $132,623.80 |
DisclosureSEC source: 0001209191-23-023469 · doc4.xml · nonDerivative · entry 2 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $16.15 per share. The range of sales prices on the transaction date was $15.82 to $16.40 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 19:12 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 4,288 | $15.98 | $68,522.24 |
DisclosureSEC source: 0001209191-23-023469 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,712 F1 · price: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on September 30, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:44 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-23-015609 · doc4.xml · derivative · entry 2 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:44 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015609 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| October 10, 2022 Filed Oct 11, 2022 16:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $16.89 | $0.00 |
DisclosureSEC source: 0001209191-22-053313 · doc4.xml · derivative · entry 2 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-10-09 F2 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 10, 2022 Filed Oct 11, 2022 16:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053313 · doc4.xml · nonDerivative · entry 1 Pizzuti Dana · CIK 0001948238 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on March 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.